title: [Central nervous system demyelinating disease-associated uveitis].
abstract: OBJECTIVE
  To describe the epidemiology, clinical features and visual prognosis in uveitis associated with demyelinating disease (DD) of the CNS.
  
  
  METHODS
  A clinical, retrospective, and descriptive study was performed. Data regarding age at presentation, gender, time from onset was recorded, as well as, type of uveitis, complications, treatment and initial and final visual acuity (BCVA) on all patients with DD-associated uveitis diagnosed in our Unit between January 2009 and June 2011.
  
  
  RESULTS
  Five women and 4 men were finally included (1.3% of 697 with uveitis). There was associated multiple sclerosis in 78% of cases. Mean age at presentation was 36.6 years for uveitis and 40 years for DD. The uveitis preceded the DD in 3 cases (33%). Typically, uveitis was bilateral (89%), chronic (89%), intermediate (89%), and associated with previous inflammation (29%), with synechiae (65%), and granulomatous (44%). The most frequent complications were cataract (71%) and macular oedema (53%). Besides local treatment, uveitis was managed with systemic steroids (78%), immunosuppressants (44%), and surgery (41% of eyes). After a mean follow up of 5 years, 47% of the eyes had a worse BCVA, among which, 12% lost ≥ 3 Snellen lines. The only patient treated with interferon (IFN), remained stable without treatment for the last 7 years.
  
  
  CONCLUSIONS
  DD-associated uveitis typically affected young adult women with intermediate-anterior uveitis of chronic, bilateral and synechiae type. Complications are common and there is a risk of visual loss, despite treatment. IFN therapy may be an effective alternative to be investigated.
authors.affiliation: Hospital Clínic i Provincial de Barcelona, Institut Clínic d'Oftalmologia (ICOF), Barcelona, España. llorens.victor@gmail.com
authors.forename: V
authors.initials: V
authors.lastname: Llorenç
authors.forename: A
authors.initials: A
authors.lastname: Rey
authors.forename: M
authors.initials: M
authors.lastname: Mesquida
authors.forename: L
authors.initials: L
authors.lastname: Pelegrín
authors.forename: A
authors.initials: A
authors.lastname: Adán
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002386:Cataract / Q000209:etiology; D003131:Combined Modality Therapy; D003711:Demyelinating Diseases / Q000150:complications*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy; D009188:Myelitis, Transverse / Q000150:complications; D018918:Phacoemulsification; D012189:Retrospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D014821:Vitrectomy; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016898:Interferon-alpha